126 related articles for article (PubMed ID: 37978032)
1. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced Prostate Cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis.
Sivakumar S; Lee JK; Moore JA; Hopkins J; Newberg JY; Madison R; Graf R; Schrock AB; Kobetz E; Vince R; Franco I; Seldon C; Frampton GM; Mills J; Venstrom J; Mahal BA
Lancet Digit Health; 2023 Jun; 5(6):e380-e389. PubMed ID: 37236698
[TBL] [Abstract][Full Text] [Related]
3. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Antonarakis ES; Tierno M; Fisher V; Tukachinsky H; Alexander S; Hamdani O; Hiemenz MC; Huang RSP; Oxnard GR; Graf RP
Prostate; 2022 May; 82(7):867-875. PubMed ID: 35286728
[TBL] [Abstract][Full Text] [Related]
5. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
6. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.
Chung JH; Dewal N; Sokol E; Mathew P; Whitehead R; Millis SZ; Frampton GM; Bratslavsky G; Pal SK; Lee RJ; Necchi A; Gregg JP; Lara P; Antonarakis ES; Miller VA; Ross JS; Ali SM; Agarwal N
JCO Precis Oncol; 2019; 3():. PubMed ID: 31218271
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM; Lilly MB; Sonpavde G; Lin E; Nussenzveig RH; Barata PC; Yandell M; Nagy RJ; Kiedrowski L; Agarwal N; Sartor O
Oncologist; 2020 Apr; 25(4):327-333. PubMed ID: 32297439
[TBL] [Abstract][Full Text] [Related]
10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
11. An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.
Dawson NA; Zibelman M; Lindsay T; Feldman RA; Saul M; Gatalica Z; Korn WM; Heath EI
Mol Cancer Ther; 2020 Jun; 19(6):1373-1382. PubMed ID: 32220973
[TBL] [Abstract][Full Text] [Related]
12. Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
Necchi A; Cucchiara V; Grivas P; Bratslavsky G; Jacob J; Spiess PE; Sokol ES; Killian JK; Lin D; Ramkissoon S; Huang RSP; Madison RW; Venstrom JM; Schrock AB; Danziger N; Decker B; Gjoerup O; Graf RP; Oxnard GR; Tukachinsky H; Ross JS
Cancer; 2021 Dec; 127(24):4557-4564. PubMed ID: 34379803
[TBL] [Abstract][Full Text] [Related]
13. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
[TBL] [Abstract][Full Text] [Related]
14. Clinicogenomic characterization of prostate cancer liver metastases.
Alshalalfa M; Seldon C; Franco I; Vince R; Carmona R; Punnen S; Kaochar S; Dess R; Kishan A; Spratt DE; Sharma J; Dal Pra A; Pollack A; Abramowitz MC; Mahal BA
Prostate Cancer Prostatic Dis; 2022 Feb; 25(2):366-369. PubMed ID: 35022600
[TBL] [Abstract][Full Text] [Related]
15. Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions.
Chalmers ZR; Burns MC; Ebot EM; Frampton GM; Ross JS; Hussain MHA; Abdulkadir SA
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):558-566. PubMed ID: 33420417
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
[TBL] [Abstract][Full Text] [Related]
17. A 12-gene panel in estimating hormone-treatment responses of castration-resistant prostate cancer patients generated using a combined analysis of bulk and single-cell sequencing data.
Huang J; Liu D; Li J; Xu J; Dong S; Zhang H
Ann Med; 2023; 55(2):2260387. PubMed ID: 37729607
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers.
Gong T; Jaratlerdsiri W; Jiang J; Willet C; Chew T; Patrick SM; Lyons RJ; Haynes AM; Pasqualim G; Brum IS; Stricker PD; Mutambirwa SBA; Sadsad R; Papenfuss AT; Bornman RMS; Chan EKF; Hayes VM
Genome Med; 2022 Aug; 14(1):100. PubMed ID: 36045381
[TBL] [Abstract][Full Text] [Related]
19. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
